

# Transmission, infectivity, and neutralization of a spike

Cell

184, 3426-3437.e8

DOI: [10.1016/j.cell.2021.04.025](https://doi.org/10.1016/j.cell.2021.04.025)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using high-resolution melting analysis. <i>Journal of Toxicological Sciences</i> , 2021, 46, 471-476.	0.7	27
6	The surveillance of spike protein for patients with COVID-19 detected in Hong Kong in 2020. <i>Journal of Medical Virology</i> , 2021, 93, 5644-5647.	2.5	9
9	The Spike of Concern—The Novel Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1002.	1.5	92
13	Rapid generation of potent antibodies by autonomous hypermutation in yeast. <i>Nature Chemical Biology</i> , 2021, 17, 1057-1064.	3.9	59
14	Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants. <i>Frontiers in Medical Technology</i> , 2021, 3, 694347.	1.3	22
15	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <i>Frontiers in Microbiology</i> , 2021, 12, 698944.	1.5	40
16	SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2635.	1.0	36
17	Nucleic Acid Testing of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6150.	1.8	42
18	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
19	Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State. <i>Clinical Infectious Diseases</i> , 2022, 74, 1089-1092.	2.9	38
20	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	1.6	54
21	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
22	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
23	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
25	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.	1.5	12
26	Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 285.	7.1	8
27	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
28	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421

#	ARTICLE	IF	CITATIONS
29	Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
30	Conformational Variability Correlation Prediction of Transmissibility and Neutralization Escape Ability for Multiple Mutation SARS-CoV-2 Strains using SSSCPreds. <i>ACS Omega</i> , 2021, 6, 19323-19329.	1.6	6
32	The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. <i>Precision Clinical Medicine</i> , 2021, 4, 149-154.	1.3	7
33	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
34	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	5.1	73
36	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1623-1630.	2.9	42
38	The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. <i>Current Biology</i> , 2021, 31, R918-R929.	1.8	246
39	SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. <i>Microorganisms</i> , 2021, 9, 1542.	1.6	521
40	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
41	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
42	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. <i>Critical Care</i> , 2021, 25, 244.	2.5	186
45	Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). <i>Frontiers in Medicine</i> , 2021, 8, 702066.	1.2	14
49	The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R. <i>Vaccines</i> , 2021, 9, 937.	2.1	12
51	Predominance of the SARS-CoV-2 Lineage P.1 and Its Sublineage P.1.2 in Patients from the Metropolitan Region of Porto Alegre, Southern Brazil in March 2021. <i>Pathogens</i> , 2021, 10, 988.	1.2	11
52	Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0092121.	1.8	140
56	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
57	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. <i>Viruses</i> , 2021, 13, 1693.	1.5	69
58	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. <i>Environmental Microbiology</i> , 2022, 24, 2615-2629.	1.8	23

#	ARTICLE	IF	CITATIONS
60	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
62	Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant. <i>Biomolecules</i> , 2021, 11, 1244.	1.8	17
64	An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. <i>Frontiers in Pharmacology</i> , 2021, 12, 717757.	1.6	28
66	Jumping a Moving Train: SARS-CoV-2 Evolution in Real Time. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S96-S105.	0.6	9
68	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
70	Novel SARS-CoV-2 variants: the pandemics within the pandemic. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1109-1117.	2.8	290
71	Î±-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757691.	2.2	2
72	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 37, 109825.	2.9	73
73	Interleukin-1RA Mitigates SARS-CoV-2-Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2773-2785.	1.1	20
74	Application of omics technology to combat the COVID-19 pandemic. <i>MedComm</i> , 2021, 2, 381-401.	3.1	11
75	Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States. <i>Journal of Medical Virology</i> , 2022, 94, 310-317.	2.5	59
76	Could live attenuated vaccines better control COVID-19?. <i>Vaccine</i> , 2021, 39, 5719-5726.	1.7	29
78	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
79	Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. <i>Microbiology Spectrum</i> , 2021, 9, e0073321.	1.2	22
81	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
82	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
83	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
85	Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies. <i>Journal of Molecular Biology</i> , 2021, 433, 167155.	2.0	53

#	ARTICLE	IF	CITATIONS
86	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
87	Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Pathology Research and Practice</i> , 2021, 225, 153565.	1.0	8
88	Association of E484K spike protein mutation with SARS-CoV-2 infection in vaccinated persons—Maryland, January â€“ May 2021. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	10
89	Impact of the Delta variant on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 1201-1209.	2.0	177
90	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
91	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
92	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, e1-e3.	1.7	146
93	Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. <i>EClinicalMedicine</i> , 2021, 40, 101129.	3.2	176
94	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <i>Journal of Biological Chemistry</i> , 2021, 297, 101151.	1.6	42
95	GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112011.	2.5	6
96	The existence, spread, and strategies for environmental monitoring and control of SARS-CoV-2 in environmental media. <i>Science of the Total Environment</i> , 2021, 795, 148949.	3.9	4
97	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. <i>Virology</i> , 2021, 563, 134-145.	1.1	74
98	Wastewater SARS-CoV-2 monitoring as a community-level COVID-19 trend tracker and variants in Ohio, United States. <i>Science of the Total Environment</i> , 2021, 801, 149757.	3.9	107
99	Diagnostic pre-screening method based on N-gene dropout or delay to increase feasibility of SARS-CoV-2 VOC B.1.1.7 detection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115491.	0.8	16
100	SARS-CoV-2 Variants of Concern. <i>Yonsei Medical Journal</i> , 2021, 62, 961.	0.9	183
101	Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): Protocol for a Multisite Longitudinal Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e31574.	0.5	17
102	Structureâ€“Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5133-5140.	2.5	21
103	Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. <i>IScience</i> , 2021, 24, 103341.	1.9	47

#	ARTICLE	IF	CITATIONS
104	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
105	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	1.6	33
106	Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential. <i>Viruses</i> , 2021, 13, 2114.	1.5	10
107	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
108	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80
110	Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. <i>Journal of Infectious Diseases</i> , 2021, 224, 1821-1829.	1.9	53
111	Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617. <i>Frontiers in Microbiology</i> , 2021, 12, 750725.	1.5	11
115	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. <i>Communications Biology</i> , 2021, 4, 1196.	2.0	49
117	SARS-CoV-2 Variants Detection Using TaqMan SARS-CoV-2 Mutation Panel Molecular Genotyping Assays. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 4471-4479.	1.1	30
119	Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity. <i>Vaccines</i> , 2021, 9, 1168.	2.1	19
120	Genetic Analysis of SARS-CoV-2 Variants in Mexico during the First Year of the COVID-19 Pandemic. <i>Viruses</i> , 2021, 13, 2161.	1.5	32
121	Investigation of SARS-CoV-2 Epsilon Variant and Hospitalization Status by Genomic Surveillance in a Single Large Health System During the 2020-2021 Winter Surge in Southern California. <i>American Journal of Clinical Pathology</i> , 2022, 157, 649-652.	0.4	9
122	Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021. <i>Virology</i> , 2022, 565, 29-37.	1.1	7
123	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. <i>Frontiers in Immunology</i> , 2021, 12, 742167.	2.2	32
124	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 747830.	2.2	69
125	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	1.7	63
126	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
127	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. <i>EBioMedicine</i> , 2021, 73, 103675.	2.7	26

#	ARTICLE	IF	CITATIONS
129	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. Cellular and Molecular Life Sciences, 2021, 78, 7967-7989.	2.4	40
130	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. Frontiers in Immunology, 2021, 12, 744242.	2.2	44
131	Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations. Infection, Genetics and Evolution, 2022, 97, 105153.	1.0	16
132	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerging Microbes and Infections, 2022, 11, 18-29.	3.0	25
133	A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes and Infections, 2022, 11, 147-157.	3.0	25
134	A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. MBio, 2021, , e0293621.	1.8	1
135	A defective viral genome strategy elicits broad protective immunity against respiratory viruses. Cell, 2021, 184, 6037-6051.e14.	13.5	33
136	Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. Journal of Medical Virology, 2022, 94, 1300-1314.	2.5	32
137	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. MBio, 2021, 12, e0297521.	1.8	24
138	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. Vaccines, 2021, 9, 1317.	2.1	35
139	Re-emergence of Gamma-like-II and emergence of Gamma-S:E661D SARS-CoV-2 lineages in the south of Brazil after the 2021 outbreak. Virology Journal, 2021, 18, 222.	1.4	8
140	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. ACS Infectious Diseases, 2022, 8, 29-58.	1.8	32
141	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. IScience, 2021, 24, 103467.	1.9	26
142	Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Genes and Diseases, 2022, 9, 1290-1300.	1.5	13
144	Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nature Microbiology, 2022, 7, 277-288.	5.9	37
145	A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. International Journal of Biological Sciences, 2022, 18, 889-900.	2.6	40
146	Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India. Archives of Virology, 2022, 167, 393-403.	0.9	5
147	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. Applied Sciences (Switzerland), 2022, 12, 665.	1.3	8

#	ARTICLE	IF	CITATIONS
148	A fractal scaling analysis of the SARS-CoV-2 genome sequence. <i>Biomedical Signal Processing and Control</i> , 2022, 73, 103433.	3.5	4
151	Memory Gaps in America: Mutational and Immunoinformatic Analysis of Evolving SARS-CoV-2 Variants of Concern and Interest. <i>ImmunoHorizons</i> , 2022, 6, 1-7.	0.8	0
153	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
154	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. <i>MBio</i> , 2022, 13, e0323821.	1.8	11
157	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
158	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
160	Shorter Incubation Period among Unvaccinated Delta Variant Coronavirus Disease 2019 Patients in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1127.	1.2	24
161	Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display. <i>Cell Reports</i> , 2022, 38, 110348.	2.9	14
162	Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. <i>Frontiers in Microbiology</i> , 2021, 12, 817200.	1.5	14
164	Severe Acute Respiratory Syndrome Type 2â€Causing Coronavirus: Variants and Preventive Strategies. <i>Advanced Science</i> , 2022, 9, e2104495.	5.6	16
165	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. <i>Viruses</i> , 2022, 14, 144.	1.5	12
166	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
167	Establishment of a Rapid Typing Method for Coronavirus Disease 2019 Mutant Strains Based on PARMS Technology. <i>Micromachines</i> , 2022, 13, 145.	1.4	0
168	Structural biology of SARS-CoV-2: open the door for novel therapies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 26.	7.1	139
169	Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 824-837.	1.9	49
170	Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomal Bovineâ€Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 655-663.	1.9	4
171	Charge Matters: Mutations in Omicron Variant Favor Binding to Cells. <i>ChemBioChem</i> , 2022, 23, e202100681.	1.3	62
172	Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2368-2381.	2.0	7



#	ARTICLE	IF	CITATIONS
173	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
174	Multiplex PCR Assays for Identifying all Major Severe Acute Respiratory Syndrome Coronavirus 2 Variants. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 309-319.	1.2	36
175	Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India. <i>Microbial Pathogenesis</i> , 2022, 164, 105404.	1.3	14
176	The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. <i>PLoS Pathogens</i> , 2022, 18, e1009914.	2.1	26
177	Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Alpha Variant—United States, 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e122-e132.	2.9	18
178	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
179	Emerging Vaccine-Breakthrough SARS-CoV-2 Variants. <i>ACS Infectious Diseases</i> , 2022, 8, 546-556.	1.8	59
180	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
181	SARS-CoV-2—Specific Vaccine Candidates; the Contribution of Structural Vaccinology. <i>Vaccines</i> , 2022, 10, 236.	2.1	14
182	Imparting reusable and SARS-CoV-2 inhibition properties to standard masks through metal-organic nano-coatings. <i>Journal of Hazardous Materials</i> , 2022, 431, 128441.	6.5	16
183	The variants of SARS-CoV-2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	2.5	29
184	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
185	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	2.3	112
186	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. <i>Cell Reports</i> , 2021, 37, 110156.	2.9	67
187	Rapid assessment of SARS-CoV-2—evolved variants using virus-like particles. <i>Science</i> , 2021, 374, 1626-1632.	6.0	216
188	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. <i>Viruses</i> , 2021, 13, 2485.	1.5	23
189	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
190	A low proportion of asymptomatic COVID-19 patients with the Delta variant infection by viral transmission through household contact at the time of confirmation in Ibaraki, Japan. <i>Global Health &amp; Medicine</i> , 2022, , .	0.6	2

#	ARTICLE	IF	CITATIONS
191	Cold atmospheric plasma for preventing infection of viruses that use ACE2 for entry. <i>Theranostics</i> , 2022, 12, 2811-2832.	4.6	8
194	Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac027.	0.4	8
195	COVID-19: A systematic review and update on prevention, diagnosis, and treatment. <i>MedComm</i> , 2022, 3, e115.	3.1	30
196	Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0068121.	1.2	5
197	Whole genome sequence analysis showing unique SARS-CoV-2 lineages of B.1.524 and AU.2 in Malaysia. <i>PLoS ONE</i> , 2022, 17, e0263678.	1.1	8
199	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
201	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
202	Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein. <i>Molecules</i> , 2022, 27, 2070.	1.7	3
203	Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. <i>MBio</i> , 2022, 13, e0203021.	1.8	10
204	Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice. <i>Journal of Medical Virology</i> , 2022, 94, 3223-3232.	2.5	12
205	The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia. <i>PeerJ</i> , 2022, 10, e13132.	0.9	9
206	A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 103960.	1.9	16
208	Conserved Targets to Prevent Emerging Coronaviruses. <i>Viruses</i> , 2022, 14, 563.	1.5	2
209	Increased Secondary Attack Rate among Unvaccinated Household Contacts of Coronavirus Disease 2019 Patients with Delta Variant in Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3889.	1.2	7
211	High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity. <i>Exploration of Immunology</i> , 0, , 133-156.	1.7	7
212	Antibody escape and global spread of SARS-CoV-2 lineage A.27. <i>Nature Communications</i> , 2022, 13, 1152.	5.8	20
213	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
214	The Runaway Evolution of SARS-CoV-2 Leading to the Highly Evolved Delta Strain. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	14

#	ARTICLE	IF	CITATIONS
215	Global trends in COVID-19. , 2022, 1, 31-39.		8
216	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9
217	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
219	Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816389.	2.2	5
220	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
221	Early Emergence Phase of SARS-CoV-2 Delta Variant in Florida, US. <i>Viruses</i> , 2022, 14, 766.	1.5	1
222	Genetic Surveillance of Five SARS-CoV-2 Clinical Samples in Henan Province Using Nanopore Sequencing. <i>Frontiers in Immunology</i> , 2022, 13, 814806.	2.2	5
223	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity. <i>Emerging Microbes and Infections</i> , 2022, 11, 1024-1036.	3.0	5
224	Human organoid models to study SARS-CoV-2 infection. <i>Nature Methods</i> , 2022, 19, 418-428.	9.0	73
225	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	2.5	22
229	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
230	A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. <i>Frontiers in Immunology</i> , 2021, 12, 789905.	2.2	7
232	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning Strategy. <i>Viruses</i> , 2022, 14, 9.	1.5	10
233	Emergence of novel combinations of SARS-CoV-2 spike receptor binding domain variants in Senegal. <i>Scientific Reports</i> , 2021, 11, 23644.	1.6	4
235	Impact of SARS-CoV-2 Mutations on Global Travel and the Increasing Number of Re-Infections: A Risk-Assessment Perspective. <i>The Open Covid Journal</i> , 2021, 1, 196-204.	0.4	2
237	Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2. <i>Biomolecules</i> , 2022, 12, 572.	1.8	8
238	US Severe Acute Respiratory Syndrome Coronavirus 2 Epsilon Variant: Highly Transmissible but With an Adjusted Muted Host T-Cell Response. <i>Clinical Infectious Diseases</i> , 2022, 75, 1940-1949.	2.9	3
239	Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. <i>Infection, Genetics and Evolution</i> , 2022, 101, 105282.	1.0	7

#	ARTICLE	IF	CITATIONS
241	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
242	COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	4
243	Variant Analysis and Strategic Clustering to Sub-Lineage of Double Mutant Strain B.1.617 of SARS-CoV-2. <i>Covid</i> , 2022, 2, 513-531.	0.7	1
244	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
245	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0000822.	1.2	17
246	Use of wastewater surveillance for early detection of Alpha and Epsilon SARS-CoV-2 variants of concern and estimation of overall COVID-19 infection burden. <i>Science of the Total Environment</i> , 2022, 835, 155410.	3.9	34
247	Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 3840-3849.	2.1	79
248	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
249	SARS-CoV-2: Evolution and Emergence of New Viral Variants. <i>Viruses</i> , 2022, 14, 653.	1.5	39
251	Impact of SARS-CoV-2 Mutations on PCR Assay Sequence Alignment. <i>Frontiers in Public Health</i> , 2022, 10, 889973.	1.3	2
252	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. <i>Translational Research</i> , 2022, 248, 11-21.	2.2	13
253	Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 138.	7.1	140
254	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
255	Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. <i>PLoS ONE</i> , 2022, 17, e0267847.	1.1	20
256	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	2.8	27
257	Emerging SARS-CoV-2 variants: Why, how, and what's next?., 2022, 1, 100029.		26
258	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
259	SARS-CoV-2 Lineage A.27: New Data from African Countries and Dynamics in the Context of the COVID-19 Pandemic. <i>Viruses</i> , 2022, 14, 1007.	1.5	5

#	ARTICLE	IF	CITATIONS
260	COVID-19 vaccines provide better protection against related pneumonia than previous symptomatic infection. <i>International Journal of Infectious Diseases</i> , 2022, 120, 142-145.	1.5	7
262	Evolution of the SARS-CoV-2 pandemic in India. <i>Medical Journal Armed Forces India</i> , 2022, 78, 264-270.	0.3	7
263	Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 866368.	2.0	21
266	Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. <i>Science</i> , 2022, 376, 1327-1332.	6.0	172
267	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. <i>Cell</i> , 2022, 185, 2279-2291.e17.	13.5	25
269	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
270	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
271	Mutations of the SARS-CoV-2 Spike Glycoprotein Detected in Cats and Their Effect on Its Structure and Function. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	1.8	4
273	Towards the discovery of potential RdRp inhibitors for the treatment of COVID-19: structure guided virtual screening, computational ADME and molecular dynamics study. <i>Structural Chemistry</i> , 2022, 33, 1569-1583.	1.0	5
274	Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332.	1.5	12
275	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
276	Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3107-3122.	2.5	5
277	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
278	Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	10
279	3D Human Organoids: The Next "Viral" Model for the Molecular Basis of Infectious Diseases. <i>Biomedicines</i> , 2022, 10, 1541.	1.4	6
280	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. <i>PLoS Pathogens</i> , 2022, 18, e1010592.	2.1	13
281	Detection of SARS-CoV-2 intra-host recombination during superinfection with Alpha and Epsilon variants in New York City. <i>Nature Communications</i> , 2022, 13, .	5.8	22
282	Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng. <i>Journal of Ginseng Research</i> , 2023, 47, 123-132.	3.0	5

#	ARTICLE	IF	CITATIONS
284	From 15 Minutes to 15 Seconds: How the Delta Variant Changed the Risk of Exposure to COVID-19. A Comparative Epidemiological Investigation Using Community Mobility Data From the Metropolitan Area of Genoa, Italy. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
285	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	26
286	Genomic surveillance of SARS-CoV-2 in US military compounds in Afghanistan reveals multiple introductions and outbreaks of Alpha and Delta variants. <i>BMC Genomics</i> , 2022, 23, .	1.2	2
287	Two Years of Evolutionary Dynamics of SARS-CoV-2 in Mexico, With Emphasis on the Variants of Concern. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
288	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
289	Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
290	Insight into Genetic Characteristics of Identified SARS-CoV-2 Variants in Egypt from March 2020 to May 2021. <i>Pathogens</i> , 2022, 11, 834.	1.2	9
291	Molecular characterization of SARS-CoV-2 detected in Tokyo, Japan during five waves: Identification of the amino acid substitutions associated with transmissibility and severity. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
292	Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4501-4516.	1.9	8
293	The Local Topological Free Energy of the SARS-CoV-2 Spike Protein. <i>Polymers</i> , 2022, 14, 3014.	2.0	1
294	Molecular adaptations during viral epidemics. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
295	Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. <i>Virus Evolution</i> , 2022, 8, .	2.2	10
296	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
297	Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies. <i>Communications Biology</i> , 2022, 5, .	2.0	5
298	Emergence and evolution of SARS-CoV-2 genetic variants during the Cuban epidemic. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100104.	0.4	3
299	Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. <i>Microorganisms</i> , 2022, 10, 1676.	1.6	5
302	Promising natural products against <scp>SARSâ€CoV</scp>â€2: Structure, function, and clinical trials. <i>Phytotherapy Research</i> , 2022, 36, 3833-3858.	2.8	9
304	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	2.0	3

#	ARTICLE	IF	CITATIONS
305	Multimodal surveillance of SARS-CoV-2 at a university enables development of a robust outbreak response framework. <i>Med</i> , 2022, 3, 883-900.e13.	2.2	15
306	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
307	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
308	Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies. <i>Communications in Information and Systems</i> , 2022, 22, 339-361.	0.3	2
309	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
310	Will New Variants Emerge after Delta and Omicron?. , 2022, 13, 1317.		1
311	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
312	Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1073-1085.	0.9	2
314	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
316	Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection. <i>Vaccines</i> , 2022, 10, 1504.	2.1	2
318	Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11058.	1.8	2
319	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
320	An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. <i>Science China Life Sciences</i> , 0, , .	2.3	2
321	Proteomics-based mass spectrometry profiling of SARS-CoV-2 infection from human nasopharyngeal samples. <i>Mass Spectrometry Reviews</i> , 2024, 43, 193-229.	2.8	2
322	Murine Hepatitis Virus, a Biosafety Level 2 Model for SARS-CoV-2, Can Remain Viable on Meat and Meat Packaging Materials for at Least 48 Hours. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
323	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
324	Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	11
325	Intrahost SARS-CoV-2 k-mer Identification Method (iSKIM) for Rapid Detection of Mutations of Concern Reveals Emergence of Global Mutation Patterns. <i>Viruses</i> , 2022, 14, 2128.	1.5	0

#	ARTICLE	IF	CITATIONS
326	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2
327	SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. <i>Nature Microbiology</i> , 2022, 7, 1635-1649.	5.9	25
328	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
329	Variant-specific RT-qPCR for rapid screening of B.1.617 mutations in SARS-CoV-2. <i>Libyan Journal of Medicine</i> , 2022, 17, .	0.8	2
330	CHARMMâ€œGUI <i>Enhanced Sampler</i> for <scp>various collective variables</scp> and <scp>enhanced sampling methods</scp>. <i>Protein Science</i> , 2022, 31, .	3.1	9
331	Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2. <i>Viruses</i> , 2022, 14, 2178.	1.5	5
332	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
333	Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 2749-2761.	3.0	9
334	Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
335	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
337	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
338	Evolutionary Pattern Comparisons of the SARS-CoV-2 Delta Variant in Countries/Regions with High and Low Vaccine Coverage. <i>Viruses</i> , 2022, 14, 2296.	1.5	4
339	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
340	Longitudinal Analyses after COVID-19 Recovery or Prolonged Infection Reveal Unique Immunological Signatures after Repeated Vaccinations. <i>Vaccines</i> , 2022, 10, 1815.	2.1	0
342	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. <i>Nature</i> , 2022, 612, 540-545.	13.7	60
343	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
344	High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 2779.	1.4	2
345	Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses. <i>Archives of Medical Research</i> , 2022, 53, 694-710.	1.5	5



#	ARTICLE	IF	CITATIONS
346	Multiple partition Markov model for B.1.1.7, B.1.351, B.1.617.2, and P.1 variants of SARS-CoV 2 virus. Computational Statistics, 0, , .	0.8	1
347	SARS-CoV-2 variants: Impact on biological and clinical outcome. Frontiers in Medicine, 0, 9, .	1.2	7
348	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. IScience, 2022, 25, 105507.	1.9	10
349	The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study. International Journal of Molecular Sciences, 2022, 23, 13502.	1.8	6
350	Mutations in Spike Gene of SARS-CoV-2 that Are Associated with a Higher Viral Load: A Clinical Case Study. Case Reports in Clinical Medicine, 2022, 11, 474-486.	0.1	1
351	Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. Medicina (Lithuania), 2022, 58, 1733.	0.8	2
352	Modelling optimal lockdowns with waning immunity. Economic Theory, 2024, 77, 197-234.	0.5	7
353	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. Biomolecules, 2022, 12, 1742.	1.8	6
354	Inferring selection effects in SARS-CoV-2 with Bayesian Viral Allele Selection. PLoS Genetics, 2022, 18, e1010540.	1.5	8
355	Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawaiâ€™i to facilitate public-health policies. PLoS ONE, 2022, 17, e0278287.	1.1	0
356	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Nature Communications, 2022, 13, .	5.8	17
357	An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study. Metabolites, 2022, 12, 1206.	1.3	6
358	The SARS-CoV-2 Delta (B.1.617.2) variant with Spike N501Y mutation in the shadow of Omicron emergence. Heliyon, 2022, , e12650.	1.4	0
359	Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. Microorganisms, 2023, 11, 30.	1.6	11
360	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Scientific Reports, 2022, 12, .	1.6	5
361	Mixing age and risk groups for accessing COVID-19 vaccines: a modelling study. BMJ Open, 2022, 12, e061139.	0.8	1
362	SARS-CoV-2 Lineage P.4 Detection in Southeast Brazil: A Retrospective Genomic and Clinical Overview. Covid, 2022, 2, 1768-1777.	0.7	1
363	Key mutations in the spike protein of SARSâ€™CoVâ€™2 affecting neutralization resistance and viral internalization. Journal of Medical Virology, 2023, 95, .	2.5	15

#	ARTICLE	IF	CITATIONS
366	The Relationship between the Transmission of Different SARS-CoV-2 Strains and Air Quality: A Case Study in China. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1943.	1.2	1
367	The case fatality rate of COVID-19 during the Delta and the Omicron epidemic phase: A meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
369	Dual-Domain Reporter Approach for Multiplex Identification of Major SARS-CoV-2 Variants of Concern in a Microarray-Based Assay. <i>Biosensors</i> , 2023, 13, 269.	2.3	1
370	Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. <i>Viruses</i> , 2023, 15, 593.	1.5	2
371	Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. <i>International Immunopharmacology</i> , 2023, 117, 109929.	1.7	2
372	Delta (B1.617.2) variant of SARS-CoV-2 induces severe neurotropic patterns in K18-hACE2 mice. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
373	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
374	Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. <i>Cell Discovery</i> , 2023, 9, .	3.1	2
375	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
376	Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	16
381	Omicron variant evolved: Signs, symptoms and complications. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
395	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
403	Research on Variation of Sars-Cov-2 and Rapid Detection. , 2023, , .		0
410	Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. <i>Chemical Papers</i> , 2024, 78, 2123-2154.	1.0	0